Diclofenac for gout: does it help during an attack, how to take it, and when is it dangerous?

Diclofenac is classified as an acute gout reliever, not a long-term disease control medication. The UK's National Institute for Health and Care Excellence recommends a nonsteroidal anti-inflammatory drug, colchicine, or a short course of oral corticosteroids as first-line treatment for a gout attack, taking into account comorbidities, medications being taken, and patient preference. The American College of Rheumatology also lists nonsteroidal anti-inflammatory drugs, colchicine, and corticosteroids as preferred first-line treatments for a gout attack. [1]

This means that diclofenac is not the "best drug for everyone," but rather one of a group of drugs that may be appropriate for some patients. The American College of Rheumatology specifically emphasizes that the choice between colchicine, nonsteroidal anti-inflammatory drugs, and glucocorticosteroids should be determined by patient characteristics, tolerability, comorbidities, availability, and previous treatment experience. [2]

Diclofenac reduces inflammation and pain by inhibiting prostaglandin synthesis through cyclooxygenase inhibition. It does not lower uric acid levels or address the underlying cause of gout if hyperuricemia persists. Therefore, the drug helps to survive an attack but does not prevent the formation of new crystals in the long term. [3]

In practice, systemic forms of medication, such as tablets, capsules, and sometimes rectal forms, are primarily discussed for gout. Systemic anti-inflammatory regimens are featured in treatment guidelines for attacks, while topical forms such as gels are considered a different clinical approach and are not considered the basis for treating acute gouty arthritis. [4]

Another important principle is early treatment. The American College of Rheumatology emphasizes the value of early intervention during an attack, and the UK's National Institute for Health and Care Excellence recommends choosing a first-line treatment immediately, without delaying the initiation of anti-inflammatory therapy. This is especially important for diclofenac, as its purpose is to quickly suppress the inflammatory wave, rather than to "finish off" an attack that has already begun. [5]

Question	Practical answer
Is diclofenac a first-line drug for an attack?	Yes, as one of the options in the group of non-steroidal anti-inflammatory drugs
Does it lower uric acid?	No
Is it suitable for the permanent treatment of gout?	No
Can it be considered the best remedy for all patients?	No
The main function of diclofenac	Quickly reduce pain and inflammation during an attack

Source for the table: recommendations for the treatment of gout attacks and the official instructions for the drug. [6]

How is diclofenac typically used for gout?

Official reference books and instructions agree that for adults, systemic forms of diclofenac are typically prescribed in a total daily dose of 75 to 150 milligrams, and the maximum daily dose for many oral forms is 150 milligrams. The British National Formulary for Acute Gout Attacks lists a dosage of 75-150 milligrams per day in 2-3 divided doses in the search fragment, while the official instructions for the extended-release form list 100 milligrams per day, with a possible increase to 150 milligrams using conventional forms. [7]

In practice, the specific regimen depends on the dosage form. The UK National Health Service recommends that tablets and capsules are typically taken 2-3 times daily, while for extended-release forms, a doctor may prescribe a less frequent regimen. Therefore, a patient should not transfer the dosage from one diclofenac form to another without further clarification, as the regular-release tablet and the extended-release tablet are not completely interchangeable in terms of dosage regimen. [8]

To reduce stomach irritation, tablets and capsules are usually recommended to be taken with milk or after meals. The UK National Health Service specifically states that taking them after a meal or snack makes stomach irritation less likely. This does not completely eliminate the risk of ulcers or bleeding, but it does help reduce common stomach discomfort in some patients. [9]

Diclofenac is not intended for long-term, uncontrolled use for gout. The UK National Health Service emphasizes that it is best taken at the lowest effective dose for the shortest possible time, and the official instructions reiterate the same principle. In other words, during an attack, the drug is used in short courses to relieve inflammation, rather than as a continuous daily regimen. [10]

In terms of overall pain relief, tablets and capsules begin working fairly quickly. The UK National Health Service states that oral diclofenac typically begins to work within 20-30 minutes, while rectal forms act more slowly. For a gout attack, this doesn't mean complete pain relief within half an hour, but it explains why the drug is often considered a quick-start anti-inflammatory treatment. [11]

Practical parameter	What is important to remember
Typical daily dose for adults	75-150 milligrams
Maximum daily dose for many oral forms	150 milligrams
Frequency of taking conventional forms	Usually 2-3 times a day
How to take	After meals, snacks or with milk
The main principle of the course	Minimum effective dose for the minimum necessary period

Source for table: National Formulary, official guidance and NHS materials. [12]

When diclofenac is contraindicated for gout or requires special caution

The most obvious limitation concerns the stomach and intestines. The official instructions for diclofenac state that the drug is contraindicated in active gastric or intestinal ulcers, bleeding or perforation, or a history of ulceration or hemorrhage associated with previous use of nonsteroidal anti-inflammatory drugs. This means that a patient with a significant ulcer history should not start diclofenac on their own simply because "it helped before." [13]

Cardiovascular precautions are also very important. The UK regulatory warning and official instructions state that diclofenac is contraindicated in patients with established coronary artery disease, peripheral arterial disease, cerebrovascular disease, and severe heart failure. This is especially relevant for patients with gout, as gout itself is often associated with hypertension, obesity, metabolic syndrome, and cardiovascular risk. [14]

Kidney and liver function are also important. The official instructions for diclofenac contraindicate it in patients with liver or renal impairment, and caution is required in mild to moderate renal or hepatic impairment. The UK National Health Service also recommends informing your doctor in advance of any severe kidney or liver disease, or heart failure. [15]

Pregnancy is another significant risk factor. Official guidelines prohibit diclofenac during the last trimester of pregnancy, and the UK National Health Service states that the drug is generally not recommended during pregnancy and is prescribed only when the benefits outweigh the risks. During breastfeeding, systemic exposure is usually lower, and only very small amounts enter the milk, but this issue should still be discussed individually. [16]

A special risk group includes patients with asthma, allergies to aspirin and other nonsteroidal anti-inflammatory drugs, inflammatory bowel disease, bleeding disorders, and the elderly. Both the UK National Health Service and official instructions recommend special caution in these situations. For frail elderly patients, the manufacturer specifically recommends using the lowest effective dose and closely monitoring for signs of gastrointestinal bleeding. [17]

Situation	Approach to diclofenac
Active ulcer, gastrointestinal bleeding, perforation	Contraindicated
Coronary heart disease, stroke, peripheral arterial disease, severe heart failure	Contraindicated
Renal failure	Contraindicated
Liver failure	Contraindicated
Last trimester of pregnancy	Contraindicated
Old age, asthma, Crohn's disease, ulcerative colitis, coagulation disorders	Special care is needed

Source for table: Official guidance, regulatory warning and NHS materials. [18]

What side effects and drug interactions are particularly important?

The most widely discussed risk is gastrointestinal. The United States Food and Drug Administration warns that nonsteroidal anti-inflammatory drugs, including diclofenac, can cause bleeding, ulcers, and perforation of the esophagus, stomach, small intestine, and colon, with these complications occurring at any time and without warning symptoms. The official label reiterates this risk and specifically emphasizes that the consequences may be more severe in elderly patients. [19]

Cardiovascular risk is no less important. The US Food and Drug Administration notes that the drug increases the risk of myocardial infarction and stroke, a risk that can occur early in treatment and increase with longer use. The UK regulator and the manufacturer's instructions also link diclofenac to a risk of arterial thrombotic events, especially at a dose of 150 milligrams per day and with long-term treatment. [20]

Kidney and fluid retention are a third major concern. The United States Food and Drug Administration warns that nonsteroidal anti-inflammatory drugs (NSAIDs) can cause kidney toxicity, worsening kidney function, edema, and worsening heart failure, especially in dehydrated patients, the elderly, patients with impaired renal function, and those taking diuretics or drugs that affect the renin-angiotensin system. The official label also lists rare but severe liver and skin complications. [21]

Diclofenac has clinically significant drug interactions. The United States Food and Drug Administration specifically states that concomitant use with anticoagulants such as warfarin increases the risk of bleeding; combination with aspirin increases gastrointestinal risk; combination with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and diuretics may worsen blood pressure control and renal function; and concomitant use with other systemic nonsteroidal anti-inflammatory drugs is not recommended. [22]

For this reason, the UK's National Institute for Health and Care Excellence recommends considering adding a proton pump inhibitor when using a nonsteroidal anti-inflammatory drug to treat a gout attack. This does not eliminate the systemic risks entirely, but it does reduce the likelihood of some gastrointestinal complications in patients with high risk. In cases of high cardiovascular or renal risk, it is sometimes better to choose colchicine or a glucocorticosteroid over diclofenac. [23]

Risk or interaction	What is important to remember
Ulcer, bleeding, perforation of the stomach and intestines	Possible at any time, sometimes without warning
Myocardial infarction and stroke	The risk is higher with higher doses and longer duration of use.
Renal impairment and fluid retention	It is especially dangerous in case of dehydration, heart failure, kidney disease.
Anticoagulants and antiplatelet agents	Increase the risk of bleeding
Aspirin	Increases gastrointestinal risk and provides no additional analgesic benefit
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics	May impair blood pressure control and kidney function
Proton pump inhibitor	Often worth considering for gastroprotection

Source for table: official instructions, materials of the Food and Drug Administration of the United States of America and recommendations of the National Institute for Health and Care Excellence of the UK. [24]

How does diclofenac compare to colchicine and glucocorticosteroids?

Current guidelines do not recommend diclofenac as the preferred agent for every attack. The American College of Rheumatology and the UK's National Institute for Health and Care Excellence list nonsteroidal anti-inflammatory drugs, colchicine, and glucocorticosteroids as the first line of treatment. This emphasizes that the issue is not resolved by dogma, but by the balance between efficacy and safety in a specific individual. [25]

A Cochrane review found that nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in treating acute gout attacks compared with placebo. The same review also found that selective cyclooxygenase inhibitors (COXIs) and non-selective NSAIDs likely provide comparable benefits in terms of pain, function, and inflammation, although non-selective NSAIDs, such as diclofenac, are likely to have higher rates of discontinuation due to adverse events and overall side effects. [26]

Therefore, diclofenac is a viable option, but not a universal winner. When a patient has a high risk of gastrointestinal bleeding, severe hypertension, cardiovascular disease, chronic kidney disease, or the need for anticoagulants, the benefits of diclofenac quickly diminish. In such cases, the physician often chooses an alternative approach, such as colchicine or a short course of glucocorticosteroids. [27]

There's another practical detail. Systemic forms of diclofenac are used to treat attacks as a full-fledged anti-inflammatory therapy, not as a cosmetic topical treatment. Therefore, in a true, severe attack of gout, systemic treatment is the first choice, not a topical gel, which may be useful for other types of pain but is not central to recommendations for acute gouty arthritis. [28]

Another important clinical sign: if attacks recur and a person consistently buys diclofenac, this usually indicates not good gout control, but rather an incompletely treated condition. Even effective anti-inflammatory drugs do not solve the problem of hyperuricemia. Therefore, recurring attacks require not only a different painkiller but also a reconsideration of the entire treatment strategy. [29]

Clinical situation	Which often looks more reasonable?
There are no serious contraindications and rapid pain control is needed.	Diclofenac may be suitable
High gastrointestinal risk	Often another option or gastroprotection is needed
Significant cardiovascular risk	Diclofenac is often undesirable
Kidney disease	Diclofenac is often undesirable or contraindicated
Frequent attacks with repeated use of diclofenac	Long-term gout treatment needs to be reconsidered

Source for table: current gout flare guidelines, Cochrane review and official diclofenac safety warnings.[30]

Why diclofenac doesn't provide long-term relief for gout

Gout is considered well controlled not when pain can be relieved intermittently with diclofenac, but when uric acid levels are consistently reduced to target levels. The UK's National Institute for Health and Care Excellence recommends aiming for levels below 360 micromoles per litre, and for those with tophi, chronic gouty arthritis, or ongoing frequent attacks, consider a lower target of below 300 micromoles per litre. [31]

For this purpose, urate-lowering therapy is used with a goal-directed strategy. The UK's National Institute for Health and Care Excellence recommends offering this treatment to people with multiple or severe attacks, chronic kidney disease, tophi, chronic gouty arthritis, or structural joint damage, and the American College of Rheumatology strongly recommends initiating urate-lowering treatment at least twice a year for tophi, radiographic damage, or frequent attacks. [32]

This leads to a fundamentally important conclusion: a repeated need for diclofenac is not a sign of treatment success, but often a sign that the disease has not been brought under long-term control. The UK's National Institute for Health and Care Excellence explicitly states that urate-lowering therapy is usually continued after target uric acid levels have been achieved and is often lifelong. Diclofenac does not fulfill this role. [33]

The timing of initiating urate-lowering treatment depends on the clinical situation. The UK National Institute for Health and Care Excellence generally recommends starting such treatment 2-4 weeks after an attack has subsided, but allows for initiation during an attack if exacerbations are frequent. At this stage, prophylaxis with colchicine is sometimes considered, and if it is contraindicated or not tolerated, low-dose nonsteroidal anti-inflammatory drugs or oral glucocorticosteroids may be considered, as determined by the physician. [34]

Finally, diclofenac should not delay the diagnosis of serious conditions. The UK's National Institute for Health and Care Excellence (NIH) recommends immediate local referral if septic arthritis is suspected. The UK National Health Service (NHS) Septic Arthritis Service (SAS) urges people to seek urgent help if they experience sudden, severe joint pain, swelling, skin discoloration around the joint, and general malaise with a fever. Therefore, the first time someone experiences a hot and sharply painful joint, especially when accompanied by a fever, is not a situation for self-medication with diclofenac. [35]

What to monitor for gout	Why diclofenac alone is not enough
Uric acid level	Diclofenac does not reduce it.
Frequency of attacks	The drug does not prevent new crystal outbreaks.
Tophi and chronic joint damage	A urate-lowering strategy is needed
Long-term prevention	Usually requires ongoing therapy, not just pain relief
Exclusion of septic arthritis	Diclofenac may mask symptoms and delay diagnosis.

Source for the table: recommendations for long-term treatment of gout and material on the urgent diagnosis of septic arthritis. [36]

Frequently Asked Questions

Can you take diclofenac during a gout attack without a doctor?
Sometimes people do start it on their own, but it's not always safe. Guidelines recommend nonsteroidal anti-inflammatory drugs as the first line of treatment for an attack, but the choice depends on heart disease, kidney disease, stomach conditions, medications being taken, and the risk of bleeding. Self-medication is especially dangerous during a first attack, with fever, severe weakness, or a suspected infection. [37]

Does diclofenac reduce uric acid?
No. Diclofenac reduces inflammation and pain, but does not target uric acid control as well as allopurinol or febuxostat. This is why anti-inflammatory therapy alone is not sufficient for frequent attacks. [38]

Is it possible to take diclofenac long-term if attacks are recurring?
This is a poor strategy. The UK National Health Service and official guidelines recommend using the lowest effective dose for the shortest possible period, and for frequent attacks, seeking long-term gout control rather than endlessly repeating short courses. [39]

What are the most dangerous aspects of diclofenac?
The most serious risks are gastrointestinal bleeding, ulcers, cardiovascular complications, and deterioration of renal function. These complications are especially important in elderly patients, those with a history of ulcers, heart disease, kidney disease, and when taken in combination with anticoagulants, aspirin, and diuretics. [40]

Can diclofenac be combined with aspirin?
The usual combination of pain-relieving doses of aspirin and diclofenac is not recommended because it provides no additional benefit and increases gastrointestinal risk. If a person is taking low-dose aspirin for cardiovascular reasons, compatibility and gastrointestinal protection should be assessed individually by a physician. [41]

Can diclofenac be taken during pregnancy?
Generally, no, it's not recommended without discussing it with a doctor. It's contraindicated in the last trimester, and in earlier stages, it's not considered the drug of choice and is prescribed only when the benefits clearly outweigh the risks. [42]

Is a proton pump inhibitor necessary with diclofenac?
In many cases, it's a reasonable consideration. The UK's National Institute for Health and Care Excellence recommends considering adding a proton pump inhibitor when using a nonsteroidal anti-inflammatory drug to treat a gout attack. This is especially relevant for those with gastrointestinal risk. [43]

When should you seek urgent help, not just take diclofenac?
Urgent evaluation is necessary for the first acute hot joint, high fever, severe general malaise, rapidly increasing pain and swelling, and when septic arthritis is suspected. Gout and joint infection can sometimes resemble each other, and a delay in diagnosing the infection is dangerous. [44]

Key points from experts

John D. Fitzgerald, MD, PhD, MBA, professor of clinical medicine and rheumatologist at the University of California, Los Angeles, is the lead author of the American College of Rheumatology's gout guidelines. His work helps clarify a key clinical principle: during an attack, rapid first-line anti-inflammatory agents are needed, but with frequent flares or tophi, therapy should shift toward a sustained uric acid reduction strategy. For diclofenac, this means a clear role: it helps during an attack, but it should not replace long-term treatment. [45]

Nicola Dalbeth, MD, FRACPH, is Professor of Medicine at the University of Auckland and an academic rheumatologist who directs the gout clinical and laboratory research program. Her research has focused specifically on gout and its associated myths. The practical implications of her work align well with current clinical guidelines: pain relief is important, but sustainable disease control requires treatment of hyperuricemia, not just intermittent pain medication. [46]

Ed Roddy, Professor of Rheumatology at Keele University, Honorary Consultant Rheumatologist at Heywood Hospital, and Fellow of the Royal College of Physicians, is particularly valuable in primary care, where most gout attacks are treated. For diclofenac, the key message is this: a convenient treatment for an attack should not overshadow the more important goal of preventing further attacks, lowering uric acid levels, and early recognition of situations where "typical gout" may be masking another, more dangerous condition. [47]